2026 Annual Meeting | Industry Therapeutic Update From Alexion, AstraZeneca Rare Disease: From Pathophysiology to Practice-Expert Perspective[s] on C5 Inhibition in Anti-AChR Antibody-Positive gMG and Practical Approaches

Date Tuesday 04/21/26

Time 11:45 AM - 12:45 PM CDT Add To Calendar

Session Format This program will be presented in-person only

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Industry Therapeutic Update

Topic(s) Neuromuscular and Clinical Neurophysiology (EMG)

Learning Objectives Engage with [an expert or experts] on gMG pathophysiology and therapeutic targets, as well as clinical data and real-world meningococcal infection rates of a complement inhibitor. Hear how a real-world adult patient was started and managed on a C5 inhibitor therapy for anti-AChR antibody-positive gMG.

CME Available No CME available

Event Timeline
11:45 AM - 12:45 PM CDT	Speaker	Industry Therapeutic Update From Alexion, AstraZeneca Rare Disease: From Pathophysiology to Practice-Expert Perspective[s] on C5 Inhibition in Anti-AChR Antibody-Positive gMG and Practical Approaches

��ɫ��

��ɫ��